



COPY OF PAPERS
ORIGINALLY FILED

PATENT

Case Docket No. STEINKE.005A

Date: January 17, 2002

4


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Thomas A. Steinke
Appl. No. : 10/017,341
Filed : December 13, 2001
For : PROTECTIVE COATING
FOR STENT
Examiner : Unknown
Group Art Unit : Unknown

I hereby certify that this correspondence and all
marked attachments are being deposited with the
United States Postal Service as first class mail in
an envelope addressed to: Assistant Commissioner
for Patents, Washington, D.C. 20231, on

February 14, 2002

(Date)


Mark R. Benedict, Reg. No. 44,531


TRANSMITTAL LETTER

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231
ATTENTION: APPLICATION BRANCH

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with sixty-two (62) references that were previously submitted. Therefore, under 37 C.F.R. §1.98(d) no copies of these references need to be submitted.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Mark R. Benedict
Registration No. 44,531
Attorney of Record

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Thomas A. Steinke) Group Art Unit - Unknown
 App. No. 10/017,341)
 Filed : December 13, 2001)
 For : PROTECTIVE COATING)
 FOR STENT)
 Examiner : Unknown)

COPY OF P
 ORIGINAL

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
 Washington, D.C. 20231

Dear Sir:


Enclosed is form PTO-1449 listing references that were previously submitted. These references were previously cited in Patent Application No. 09/739,552 (attorney docket No. STEINKE.002CP2) filed on September 20, 2001 as well as supplemental references submitted on December 21, 2001. Therefore, under 37 C.F.R. § 1.98(d) no copies of these references need to be submitted. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP


Dated: 2/14/02

By: Mark R. Benedict
 Mark R. Benedict
 Registration No. 44,531
 Attorney of Record
 620 Newport Center Drive
 Sixteenth Floor
 Newport Beach, CA 92660
 (949) 760-0404

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. STEINKE.005A	APPLICATION NO. 10/017,341
 <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)</p>		APPLICANT Thomas A. Steinke	
		FILING DATE December 13, 2001	GROUP Unknown

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	5,618,299	04/08/97	Khosravi, et al.			
	2	5,556,413	09/17/96	Lam			
	3	5,449,382	09/12/95	Dayton			
	4	4,553,545	11/19/85	Maass, et al.			
	5	4,733,665	03/29/88	Palmaz			
	6	4,739,762	04/26/88	Palmaz			
	7	4,776,337	10/11/88	Palmaz			
	8	4,922,905	05/08/90	Strecker			
	9	5,192,307	03/09/93	Wall			
	10	5,266,073	11/30/93	Wall			
	11	5,306,294	04/26/94	Winston, et al.			
	12	5,397,355	03/14/95	Marin, et al.			
	13	5,423,885	06/13/95	Williams			
	14	5,441,515	08/15/95	Khosravi, et al.			
	15	5,443,500	08/22/95	Sigwart			
	16	5,476,508	12/19/95	Amstrup			
	17	5,549,662	08/27/96	Fordenbacher			
	18	5,578,075	11/26/96	Dayton			
	19	5,591,223	01/07/97	Lock, et al.			
	20	5,643,312	07/01/97	Fischell, et al.			
	21	5,643,314	07/01/97	Carpenter, et al.			
	22	5,643,339	07/01/97	Kavteladze, et al.			
	23	5,649,977	07/22/97	Campbell			
	24	5,195,984	03/23/93	Schatz			
	25	5,603,722	02/18/97	Phan, et al.			
	26	5,707,387	01/13/98	Wijay			


EXAMINER	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	

 <p>FORM PTO-1449</p> <p>U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(USE SEVERAL SHEETS IF NECESSARY)</p>	ATTY. DOCKET NO. STEINKE.005A	APPLICATION NO. 10/017,341
	APPLICANT Thomas A. Steinke	
	FILING DATE December 13, 2001	GROUP Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	27	5,725,549	03/10/98	Lam			
	28	5,733,328	03/31/98	Fordenbacher			
	29	5,735,872	04/07/98	Carpenter, et al.			
	30	5,741,293	04/21/98	Wijay			
	31	3,620,218	11/16/71	Schmitt			
	32	5,449,382	09/12/95	Dayton			
	33	5,578,075	11/26/96	Dayton			
	34	5,059,211	10/22/91	Stack, et al.			
	35	5,306,286	04/26/94	Stack, et al.			
	36	5,527,337	06/18/96	Stack, et al.			
	37	5,464,450	11/07/95	Buscemi, et al.			
	38	5,551,954	11/03/96	Buscemi, et al.			
	39	5,629,077	05/13/97	Turnlund, et al.			
	40	5,766,710	06/16/98	Turnlund, et al.			
	41	5,851,217	12/22/98	Wolff, et al.			
	42	5,851,231	12/22/98	Wolff, et al.			
	43	5,632,771	05/27/97	Boatman, et al.			
	44	5,649,977	07/22/97	Campbell			
	45	5,876,419	03/22/99	Carpenter, et al.			

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	

 <p>FORM PTO-1449</p> <p>U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(USE SEVERAL SHEETS IF NECESSARY)</p>	ATTY. DOCKET NO. STEINKE.005A	APPLICATION NO. 10/017,341
	APPLICANT Thomas A. Steinke	
	FILING DATE December 13, 2001	GROUP Unknown

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	46	WO 96/14030	05/17/96	PCT				
	47	WO 99/40874	08/19/99	PCT				
	48	WO 98/22045	05/28/98	PCT				

COPY OF
ORIGINAL

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	49	Yanhua Hu, MD, <i>Inhibition of Neointima Hyperplasia of Mouse Vein Grafts by Locally Applied Suramin</i> , Circulation, Vol. 100, August 24, 1999, pp. 861-868
	50	Hideo Yasukawa, MD, <i>Inhibition of Intimal Hyperplasia After Balloon Injury by Antibodies to Intercellular Adhesion Molecule-1 and Lymphocyte Function? Associated Antigen-1</i> , Circulation, Vol. 95, 1997 pp. 1515-1522
	51	Carmeliet, MD, et al, <i>Inhibitory Role of Plasminogen Activator Inhibitor-1 in Arterial Wound Healing and Neointima Formation</i> , Circulation, Vol. 96, 1997, pp. 3180-3191
	52	Robert M. Nerem, et al., <i>Tissue Engineering and The Vascular System</i> , Synthetic Biodegradable Polymer Scaffolds, (1997) pp. 164-185
	53	Ron Brauner, MD, <i>CONTROLLED PERIADVENTITIAL ADMINISTRATION OF VERAPAMIL INHIBITS NEOINTIMAL SMOOTH MUSCLE CELL PROLIFERATION AND AMELIORATES VASOMOTOR ABNORMALITIES IN EXPERIMENTAL VEIN BYPASS GRAFTS</i> , The Journal of Thoracic and Cardiovascular Surgery, July 1997, Vol. 114, No. 1, pp. 53-63
	54	Yoshihiro KURISU, et al., <i>Protective Effect of Beraprost Sodium, a Stable Prostacyclin Analogue, on Cardiac Allograft Vasculopathy in Rats</i> , Hiroshima J. Med. Sci., Vol. 46, No.1, March 1997, pp. 11-19
	55	S. Nikol, et al., <i>Molecular biology and post-angioplasty restenosis</i> , Atherosclerosis 123 (1996) pp.17-31
	56	Takayuki Asahara, MD, <i>Local Delivery of Vascular Endothelial Growth Factor Accelerates Reendothelialization and Attenuates Intimal Hyperplasia in Balloon-Injured Rat Carotid Artery</i> , Circulation, Vol. 91, (1995) pp. 2793-2801
	57	Takayuki Asahara, MD, et al., <i>Synergistic Effect of Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor on Angiogenesis In Vivo</i> , SUPPLEMENT II Circulation, Vol 92, No. 9, November 1, 1995, pp. II-365-371
	58	Heiko E. Von Der Leyen, et al., <i>Gene therapy neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene</i> , Proc. Natl. Acad. Sci. USA, Vol. 92, February 1995, pp. 1137-1141.
	59	Michael V. Autieri, et al., <i>ANTISENSE OLIGONUCLEOTIDES TO THE P65 SUBUNIT OF NF-Kb INHIBIT HUMAN VASCULAR SMOOTH MUSCLE CELL ADHERENCE AND PROLIFERATION AND PREVENT NEOINTIMA FORMATION IN RAT CAROTID ARTERIES</i> , Biochemical and Biophysical Research Communications, Vol. 213, No. 3, (1995) pp. 827-836
	60	Jean Francois Tanguay, MD, et al, <i>Current Status of Biodegradable Stents</i> , Contemporary Interventional Techniques, Vol. 12 No. 4, November 1994, pp. 699-713
	61	Ryuichi Morishita et al., <i>Novel In Vitro Gene Transfer Method for Study of Local Modulators in Vascular Smooth Muscle Cells</i> , Hypertension, Vol. 21, No 6, Part 2 June 1993, pp. 894-899
	62	Stephen E. Epstein, MD, et al., <i>Cytotoxic Effects of a Recombinant Chimeric Toxin on Rapidly Proliferating Vascular Smooth Muscle Cells</i> , Circulation, Vol. 84, No 2, August 1991, pp.778-787

H:\DOCS\MRB\MRB-2803\
021202

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	